1. Abourbeh, G., Dissoki, S., Jacobson, O., Litchi, A., Ben Daniel, R., Laki, D., Levitzki, A. & Mishani, E. 2007. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol 34, 55–70.
2. Aloya, R., Shirvan, A., Grimberg, H., Reshef, A., Levin, G., Kidron, D., Cohen, A. & Ziv, I. 2006. Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis 11, 2089–101.
3. Anderson, H. L., Yap, J. T., Miller, M. P., Robbins, A., Jones, T. & Price, P. M. 2003. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21, 2823–30.
4. Bading, J. R., Yoo, P. B., Fissekis, J. D., Alauddin, M. M., D’Argenio, D. Z. & Conti, P. S. 2003. Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats. Cancer Res 63, 3667–74.
5. Baker, S. D., Wirth, M., Statkevich, P., Reidenberg, P., Alton, K., Sartorius, S. E., Dugan, M., Cutler, D., Batra, V., Grochow, L. B., Donehower, R. C. & Rowinsky, E. K. 1999. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5, 309–17.